Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH.

Circulation. 2008 Mar 11;117(10):1261-8. doi: 10.1161/CIRCULATIONAHA.107.735605. Epub 2008 Feb 19.

2.

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.

Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(40):iii-iv, xv-xvi, 1-141. Review.

3.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

4.

Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.

Lyseng-Williamson KA, Plosker GL.

Pharmacoeconomics. 2006;24(7):709-26. Review.

PMID:
16802846
5.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

6.

Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, Golder S, Alfakih K, Bakhai A, Packham C, Cooper N, Abrams K, Eastwood A, Pearman A, Flather M, Gray D, Hall A.

Health Technol Assess. 2005 Jul;9(27):iii-iv, ix-xi, 1-158. Review.

7.

Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness.

Ho WK, Hankey GJ, Eikelboom JW.

Expert Opin Pharmacother. 2004 Mar;5(3):493-503. Review.

PMID:
15013918
8.

Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.

Neyt M, De Laet C, Van Brabandt H, Franco O, Ramaekers D.

Acta Cardiol. 2009 Feb;64(1):1-10. Review.

9.
10.

Medicare Part D and quality of prescription medication use in older adults.

Lau DT, Briesacher BA, Touchette DR, Stubbings J, Ng JH.

Drugs Aging. 2011 Oct 1;28(10):797-807. doi: 10.2165/11595250-000000000-00000. Review.

11.

Medicare Part D's effect on the under- and overuse of medications: a systematic review.

Polinski JM, Donohue JM, Kilabuk E, Shrank WH.

J Am Geriatr Soc. 2011 Oct;59(10):1922-33. doi: 10.1111/j.1532-5415.2011.03537.x. Epub 2011 Aug 1. Review.

12.

Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs.

Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, Rodgers A.

Lancet. 2007 Dec 15;370(9604):2054-62. Epub 2007 Dec 11. Review.

PMID:
18063025
13.

Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review.

Polinski JM, Kilabuk E, Schneeweiss S, Brennan T, Shrank WH.

J Am Geriatr Soc. 2010 Sep;58(9):1764-79. doi: 10.1111/j.1532-5415.2010.03025.x. Review.

14.

[Role of adherence to long-term drug therapy in patients with cardiovascular disease: an Italian intersocietary consensus document].

Volpe M, Degli Esposti L, Romeo F, Trimarco B, Bovenzi FM, Mastromarino V, Battistoni A.

G Ital Cardiol (Rome). 2014 Oct;15(10 Suppl 1):3S-10S. doi: 10.1714/1696.18514. Italian.

PMID:
25426833
15.

Utilization of antihypertensive drug classes among Medicare beneficiaries with hypertension, 2007 to 2009: Data Points #8.

Townsend RR, Leonard CE, de Nava KL, Molina T, Kang-Yi C, Freeman CP.

Data Points Publication Series [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011-.
2011 Nov 16.

16.

Trends in the utilization of erythropoiesis-stimulating agents among Medicare beneficiaries with kidney disease: Data Points #4.

MaCurdy T, Gibbs J, de Nava KL, Monroy A, Wernecke M, Sherpa S, Wang G, Young S, Leonard CE.

Data Points Publication Series [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011-.
2011 Mar 31.

Items per page

Supplemental Content

Write to the Help Desk